Artificial intelligence for drug discovery.
At Atomwise, we pioneered deep learning neural network approaches for structure-based small molecule drug discovery. We leverage those technologies in one of the largest applications of machine learning in the life sciences to find treatments for Alzheimer’s, cancer, diabetes, drug-resistant antibiotics and other diseases. We’ve partnered with 4 of the top-10 US pharma companies, raised over $170M from top VCs, and have 100+ diverse projects running concurrently.
We value a collaborative and transparent culture that fosters scientific and technical discussion. We strongly believe that data wins over opinions, and aim for as little dogma as possible in our decision making. Our team members have expertise in a wide range of disciplines--from computational chemistry and structural biology to cloud-native best practices--and we regularly have internal seminars open to anyone interested in learning about these topics.
About the role
We are looking for a cheminformatics scientist with strong experience in compound modeling and data for ADMET prediction to join our ml.cheminformatics team. The team is relatively small, so there are lots of opportunities for both career growth and substantial contribution towards our success.
Compensation & benefits
Atomwise is an equal opportunity employer and strives to foster an inclusive workplace. Our mission is to develop better medicines faster, and we know that we need a diverse team to develop medicines that serve diverse populations. Accordingly, Atomwise does not make any employment decisions (including but not limited to, hiring, compensation, and promotions) on the basis of race, religion, color, national origin, gender, gender identity, sexual orientation, age, veteran status, disability status, or any other characteristics protected by applicable federal, state, and local law.
We strongly encourage people of diverse backgrounds and perspectives to apply.
Atomwise Inc. patented the first deep learning technology for structure-based small molecule drug discovery. This AI technology harnesses millions of data points and thousands of protein structures to solve problems that a human chemist would take many lifetimes to solve. Atomwise has partnered with some of the world's largest pharmaceutical and agtech companies and with more than 100 leading academic institutions and hospitals, to tackle the challenges of discovering and developing better drugs and agrochemicals. Atomwise has raised over $50 million from leading venture capital firms to support the development and application of its AI technology.